Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Humacyte, Inc. before investing.

In this article, we go over a few key elements for understanding Humacyte, Inc.’s stock price such as:

• Humacyte, Inc.’s current stock price and volume
• Why Humacyte, Inc.’s stock price changed recently
• Upgrades and downgrades for HUMA from analysts
• HUMA’s stock price momentum as measured by its relative strength

About Humacyte, Inc. (HUMA)

Before we jump into Humacyte, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Want to learn more about Humacyte, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Humacyte, Inc..

Humacyte, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:01 PM, CST, Humacyte, Inc.’s stock price was $2.569.

Humacyte, Inc. is down 3.79% from its previous closing price of $2.670.

During the last market session, Humacyte, Inc.’s stock traded between $2.560 and $2.710. Currently, there are approximately 131.50 million shares outstanding for Humacyte, Inc..

Humacyte, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Humacyte, Inc. Stock Price History

Humacyte, Inc.’s (HUMA) price is currently down 3.79% so far this month.

During the month of June, Humacyte, Inc.’s stock price has reached a high of $2.930 and a low of $2.490.

Over the last year, Humacyte, Inc. has hit prices as high as $9.790 and as low as $1.150. Year to date, Humacyte, Inc.’s stock is down 49.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Humacyte, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there was 1 analyst who downgraded Humacyte, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Humacyte, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Humacyte, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Humacyte, Inc. (HUMA) by visiting AAII Stock Evaluator.

Relative Price Strength of Humacyte, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Humacyte, Inc. has a weighted four-quarter relative price strength of -22.80%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how Humacyte, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Humacyte, Inc. Stock Price: Bottom Line

As of June 11, 2025, Humacyte, Inc.’s stock price is $2.569, which is down 3.79% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Humacyte, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.